Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Jul 29, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 29, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered
Jul 27, 2020
Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 27, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it met the
Jun 22, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 22, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced preclinical data evaluating the administration of ROLONTIS ® (eflapegrastim) on the same day as
Jun 16, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 16, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS
Jun 03, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 3, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling , M.D., MBA, has been named Senior Vice President, Clinical Development.
May 27, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
May 07, 2020
BLA for ROLONTIS ® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to host webcast and conference call
May 01, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update
Apr 30, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as
Apr 28, 2020
ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET HENDERSON, Nev. --(BUSINESS WIRE)--Apr.
Apr 23, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 23, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Seth H.Z. Fischer to its Board of Directors. Mr. Fischer fills a vacancy left by Mr.
Apr 21, 2020
Management to host webcast and conference call to review data and program strategy at 8:30 a.m. ET on April 28, 2020 HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 21, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today
Mar 17, 2020
Conference call to discuss the data and strategy for the program originally scheduled for 8 a.m. ET on March 18, 2020 has been postponed HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today
Mar 11, 2020
Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the
Mar 03, 2020
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Barclays
Feb 27, 2020
BLA for ROLONTIS ® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11 th Annual Congress on Pulmonary and Respiratory Medicine in Amsterdam Spectrum plans to hold a conference call
Feb 20, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 20, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the fourth quarter and full year 2019 financial
Feb 06, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 6, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Dec 26, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 26, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously
Nov 14, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Displaying 21 - 40 of 831